Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi 110029, India.
Jai Prakash Narayan Apex Trauma Centre, All India Institute of Medical Sciences, New Delhi 110029, India.
J Glob Antimicrob Resist. 2019 Jun;17:98-102. doi: 10.1016/j.jgar.2018.10.021. Epub 2018 Oct 30.
Staphylococcus aureus causes a variety of symptoms and diseases and has been associated with high morbidity and mortality. A global population drift in clinical S. aureus isolates towards reduced antimicrobial susceptibility is being reported. In this study, the antimicrobial susceptibility profile and minimum inhibitory concentration (MIC) creep of vancomycin, linezolid, teicoplanin and rifampicin against clinical S. aureus isolates at an Indian tertiary centre from January 2012 to December 2016 were investigated.
All consecutive, non-duplicate S. aureus isolates (n=1466) recovered from hospitalised patients identified by VITEK2 were included in the study. Clinical isolates were tested against 20 antibiotics and were evaluated according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Statistical significance of the MIC creeps of four antimicrobials (vancomycin, linezolid, teicoplanin and rifampicin) was ascertained.
S. aureus isolates recovered from all clinical samples demonstrated high resistance to ampicillin, ciprofloxacin and penicillin (75-100%) and low resistance to amikacin, linezolid, netilmicin, nitrofurantoin, teicoplanin and vancomycin (0-13%). The MIC values (MIC required to inhibit 90% of the isolates) for vancomycin, linezolid and rifampicin decreased, whereas the MIC for teicoplanin increased. The change in the geometric mean MIC of rifampicin was found to be statistically significant. A statistically significant and progressive MIC creep was observed for teicoplanin and rifampicin.
Despite remaining susceptible, S. aureus is not inert to antibiotic pressure. Implementation of preventive measures in healthcare settings is required worldwide to combat the increasing number of infections by this pathogen.
金黄色葡萄球菌可引起多种症状和疾病,并与高发病率和死亡率相关。据报道,全球临床分离的金黄色葡萄球菌对抗菌药物的敏感性呈下降趋势。本研究调查了 2012 年 1 月至 2016 年 12 月在印度一家三级中心,临床分离金黄色葡萄球菌对万古霉素、利奈唑胺、替考拉宁和利福平的抗菌药物敏感性谱和最低抑菌浓度(MIC)变化。
纳入了 VITEK2 鉴定的住院患者连续、非重复金黄色葡萄球菌分离株(n=1466)。临床分离株对 20 种抗生素进行了检测,并根据临床和实验室标准协会(CLSI)指南进行了评估。对万古霉素、利奈唑胺、替考拉宁和利福平四种抗菌药物 MIC 变化的统计学意义进行了确定。
从所有临床标本中分离出的金黄色葡萄球菌对氨苄西林、环丙沙星和青霉素表现出高度耐药(75-100%),对阿米卡星、利奈唑胺、奈替米星、呋喃妥因、替考拉宁和万古霉素的耐药性较低(0-13%)。万古霉素、利奈唑胺和利福平的 MIC 值(抑制 90%分离株所需的 MIC)降低,而替考拉宁的 MIC 值增加。利福平的几何均数 MIC 变化具有统计学意义。替考拉宁和利福平的 MIC 呈渐进性、统计学显著的增加。
尽管金黄色葡萄球菌仍然敏感,但对抗菌药物的压力并非无动于衷。需要在全球范围内实施医疗保健环境中的预防措施,以对抗这种病原体引起的感染数量不断增加。